Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
HYDROCHLOROTHIAZIDE
Renal · Renal · Level 3
|
SPIRONOLACTONE
Renal · Renal · Level 3
|
|---|---|---|
| Mechanism of action | inhibit Na+ reabsorption in the early portion of the distal tubule by |
Acts in the DCT. |
| Physiological effects | Anti-HTN: (↓TPR, ↓plasma volume) |
Sedation and muscle weakness (due to electrolyte abnm) |
| Absorption | PO- BA ~50-80%. Onset 2hrs Dur 6-12hrs. |
PO - BA 70%, extensive 1st pass metb. Onset 3-4hrs, dur upto 3 days |
| Protein binding | 68% |
90% |
| Volume of distribution | 3.6-7.8L/kg |
— |
| Metabolism | Not metabolized |
Hepatic: Rapidly and extensively metabolised by deacetylation and dethiolation. Active metab: canrenone and 7-alpha-spirolactone |
| Excretion | Urine (unchanged) |
Urine and faeces |
| Half-life | 5.6-14.8hrs |
1-2hours, metab upto 24hrs |
| Adverse Effects Toxicity | ↓K+/Na+/Mg++, ↑Ca++/urea/glu/chol. |
↑K+(esp in renal failure). N/V and GI disturbances |
| Class Group | Diuretic - Thiazide |
Diuretic – Aldosterone antagonist |
| Indications Uses | heart failure and hypertension. Used in combination. mostly bound to plasma prot, and gain access to the tubule via secretion in the PCT. |
Oedema – CHF, cirrhosis with ascites, refractory. HTN, Nephrotic syndrome. With loop/thiazide to conserve K+, diagn of Conn's syndr |
| Introduction | related to the sulphonamides |
A synthetic steroid |
| Legacy Cicm Level | Level 3 |
Level 3 |
| Presentation | orange scored tablets of 25mg and combos |
25/100mg tablets |
| Route And Dose | PO. 12.5-200mg/day |
PO. 25-200mg/day |